Table 8.
Clinical safety values at baseline (W1) and at the end of the study (W16).
| Parameters (Normal Range) | Placebo Group | Supplemented Group | ||||||
|---|---|---|---|---|---|---|---|---|
| W1 | W16 | W1 | W16 | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Liver function | ||||||||
| ALT (7–55 U/L) | 21.4 | (9.1) | 21.0 | (8.5) | 25.0 | (15.9) | 25.1 | (14.7) |
| AST (8–48 U/L) | 20.2 | (5.5) | 20.1 | (5.3) | 22.4 | (6.3) | 23.3 | (10.0) |
| GGT (6–48 U/L) | 19.1 | (11.7) | 19.9 | (11.9) | 23.1 | (13.4) | 24.7 | (14.0) |
| Kidney function | ||||||||
| Urea (15–46 mg/dL) | 35.4 | (9.1) | 33.0 | (7.7) | 31.9 | (7.8) | 30.1 | (7.4) |
| Creatinine (0.6–1.3 mg/dL) | 0.79 | (0.18) | 0.74 * | (0.16) | 0.74 | (0.15) | 0.76 | (0.16) |
| Na (135–145 mmol/L) | 141.2 | (1.2) | 141.2 | (2.1) | 141.7 | (1.7) | 141.1 | (1.7) |
| K (3.6–5.2 mmol/L) | 4.3 | (0.3) | 4.3 | (0.2) | 4.3 | (0.2) | 4.3 | (0.3) |
| Heart rate (bpm) | 71.8 | (10.2) | 72.1 | (8.6) | 71.3 | (11.2) | 70.4 | (16.4) |
*—An intragroup difference between baseline (W1) and end of the study (W16) at p ≤ 0.05.